Pharmaceutical company Darnitsa increased its net profit by a third

Фармкомпания Дарница увеличила чистую прибыль на треть

The annual meeting of shareholders Darnitsa scheduled for April 3

According to the statements of the company retained earnings verification in early 2019 amounted to 1.56 billion USD.

Kyiv pharmaceutical firm Darnitsa in 2018 achieved a net profit of 449,13 million hryvnia, which is by 31.3% more than in 2017. This is stated in the report about the annual meeting of shareholders, which is scheduled for April 3.

“To approve the following allocation of profit for the results of operations for the year 2018: net profit in the amount of 449,13 million to leave the society, sending to the development and financing companies. Not to pay dividends”, – is spoken in the draft decision of the meeting.

According to the statements of the company retained earnings verification in early 2019 amounted to 1.56 billion USD.

Assets verification in 2018 grew by 30.9%, to 4.03 billion; total accounts receivable – by 49.8%, to 1.2 billion; long – term liabilities- by 2.8 times, to 879,7 million hryvnias. Current liabilities decreased by 20.3%, to 264,73 million.

In early 2019 the company was 212,43 million UAH available funds – almost twice more than the year before.

Net income from product sales in 2018 increased by 18.7% to 3,002 billion.

CHAO Pharmaceutical firm Darnitsa was founded in 1930. Is the leader in Ukraine on production of drugs in natural terms. The company’s portfolio includes about 250 names of drugs.

Beneficiaries of the company is a family zagori, including the Deputy of the Verkhovna Rada of the VIII convocation Gleb zagoriy.

Earlier it was reported that the pharmaceutical company Darnitsa new top Manager. In January its Director-General was appointed Andrew Obrisan.

News from the Reporter.net Telegram. Subscribe to our channel https://t.me/korrespondentnet

Source